Xoma: The Considered Dead is Alive and Kicking. Gilead is Way Undervalued

The Diagnosed Dead Is Far from Dying
Xoma (XOMA): Stock rallied following report announcing an upfront payment from Novartis, which multiplied the firm’s revenues 10 times over 2014. Novartis paid Xoma $37 million, Novo Nordisk paid $5 million and Pfizer paid the firm a little less than $4 million.

CEO John Varian said, “Novel antibodies and technologies created by XOMA scientists to target diseases such as cancer, diabetes and botulism will be advanced in the capable hands of Novartis, Novo Nordisk, Nanotherapeutics and Agenus, with . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.